Antagonism of microRNA-99a promotes cell invasion and down-regulates E-cadherin expression in pancreatic cancer cells by regulating mammalian target of rapamycin

Acta Histochemica

Volumn 116, Issue 5, 2014, Pages 723-729

  Li, Dan ^a   Li, Xiaohan ^a   Cao, Wei ^a   Qi, Yafei ^a   Yang, Xianghong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

E cadherin; Invasion; Mammalian target of rapamycin; MicroRNA 99a; Migration; Pancreatic cancer

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 99A; NERVE CELL ADHESION MOLECULE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; CADHERIN; MIRN99 MICRORNA, HUMAN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CELL MIGRATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RNA TRANSPORT; TUMOR INVASION; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL PROLIFERATION; DOWN REGULATION; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

MAMMALIA;

BLOTTING, WESTERN; CADHERINS; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TOR SERINE-THREONINE KINASES;

EID: 84904044710     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2013.12.013     Document Type: Article

References (27)

1. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
2. Bhardwaj A., Singh S., Singh A.P. MicroRNA-based cancer therapeutics: big hope from small RNAs. Mol Cell Pharmacol 2010, 2:213-219.
3. Chen Z., Jin Y., Yu D., Wang A., Mahjabeen I., Wang C., et al. Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma. Oral Oncol 2012, 48:686-691.
4. Cheng Y., Liu G., Pan Q., Guo S., Yang X. Elevated expression of liver X receptor alpha (LXRalpha) in myocardium of streptozotocin-induced diabetic rats. Inflammation 2013, 7:149-159.
5. Cui L., Zhou H., Zhao H., Zhou Y., Xu R., Xu X., et al. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. BMC Cancer 2012, 12:546.
6. Dai Z.J., Gao J., Kang H.F., Ma Y.G., Ma X.B., Lu W.F., et al. Targeted inhibition of mammalian target of rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cells. Drug Des Devel Ther 2013, 7:149-159.
7. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46:765-781.
8. Garzon R., Calin G.A., Croce C.M. MicroRNAs in cancer. Annu Rev Med 2009, 60:167-179.
9. Gu W., Fang S., Gao L., Tan Y., Yang Z. Clinic significance of microRNA-99a expression in human lung adenocarcinoma. J Surg Oncol 2013, 108:248-255.
10. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18:1926-1945.
11. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362:1605-1617.
12. Javle M.M., Shroff R.T., Xiong H., Varadhachary G.A., Fogelman D., Reddy S.A., et al. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 2010, 10:368.
13. Jung D.E., Wen J., Oh T., Song S.Y. Differentially expressed microRNAs in pancreatic cancer stem cells. Pancreas 2011, 40:1180-1187.
14. Kuo Y.Z., Tai Y.H., Lo H.I., Chen Y.L., Cheng H.C., Fang W.Y., et al. MiR-99a exerts anti-metastasis through inhibiting myotubularin-related protein 3 expression in oral cancer. Oral Dis 2013.
15. Li D., Liu X., Lin L., Hou J., Li N., Wang C., et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem 2011, 286:36677-36685.
16. Li X.J., Luo X.Q., Han B.W., Chen Y.Q. MicroRNA-100/99a deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways. Br J Cancer 2013, 109:2189-2198.
17. Missiaglia E., Dalai I., Barbi S., Beghelli S., Falconi M., della Peruta M., et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010, 28:245-255.
18. Nagayama K., Kohno T., Sato M., Arai Y., Minna J.D., Yokota J. Homozygous deletion scanning of the lung cancer genome at a 100-kb resolution. Genes Chromosomes Cancer 2007, 46:1000-1010.
19. Neoptolemos J.P., Cunningham D., Friess H., Bassi C., Stocken D.D., Tait D.M., et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol 2003, 14:675-692.
20. Pliarchopoulou K., Pectasides D. Pancreatic cancer: current and future treatment strategies. Cancer Treat Rev 2009, 35:431-436.
21. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
22. Sun D., Lee Y.S., Malhotra A., Kim H.K., Matecic M., Evans C., et al. miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res 2011, 71:1313-1324.
23. Sun J., Chen Z., Tan X., Zhou F., Tan F., Gao Y., et al. MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma. Med Oncol 2013, 30:411.
24. Torres A., Torres K., Pesci A., Ceccaroni M., Paszkowski T., Cassandrini P., et al. Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma. BMC Cancer 2012, 12:369.
25. Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M. Pancreatic cancer. Lancet 2011, 378:607-620.
26. Weber J.D., Gutmann D.H. Deconvoluting mTOR biology. Cell Cycle 2012, 11:236-248.
27. Wolin E.M. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors. Cancer Lett 2013, 335:1-8.